MedTrace Logo

Efficacy of SU 011248 in Head And Neck Carcinoma

NCT00408252 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-09-19

No results posted yet for this study

Summary

Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So at the light of these pre-clinical and clinical data, it seems interesting and promising to test SU011248 in these poor prognosis patients.

Conditions

  • Recurrent Disease
  • Squamous Cell Head and Neck Carcinoma
  • Palliative Treatment

Interventions

OTHER

biopsies

No intervention, only biopsy for translational project

DRUG

SU011248

no intervention

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Jean-Pascal H Machiels, MD PhD · Cliniques Universitaires St Luc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408252 on ClinicalTrials.gov